Abstract
In order to suppress the host immune reaction in subrenal capsule assay (SRCA) using normal immunocompetent mice, the effects of cyclophosphamide (CPM) pretreatment were compared to those obtained after cyclosporine A (CSA) treatment. CPM and CSA suppressed the host reaction until day 6 and day 12, respectively, however, the histological evaluation of the tumors on day 6 revealed no differences between the two groups. The cytotoxity of CPM in mouse serum against P388 cells was measured to evaluate the residual activity of CPM against the implanted tumor. No cytotoxicity was observed in the serum 36 hours after the CPM injection. In the histological analysis of clinical samples, inflammatory infiltration was observed in only 4 of 25 samples and tumor cell preservation recognized in 27 of 28 samples. A persistence of tumor cells was recognized in the samples rich in tumor cells. Adequate growth of the tumor in the control groups was obtained from 30 of 33 tumors (91 per cent), and the response rates of this assay were comparable to those of prior clinical experiences on each of these drugs. These results indicated the feasibility of SRCA with CPM pretreatment as a predictive test of chemotherapeutic agents for esophageal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bogden AE, Haskel PM, Lepage DJ, Kelton DE, Cobb WR, Esber HJ. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Expl Cell Biol 1979; 47: 281–293.
Griffin TW, Bogden AE, Reich SD, Antonelli D, Hunter RE, Ward A, Yu DT, Greene HL, Costanza ME. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer 1983; 52: 2185–2192.
Cobb WR, Bogden AE, Reich SD, Griffin TW, Kelton DE, LePage DJ. Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay. Cancer Treat Rep 1983; 67: 173–178.
Edelstein MB, Fiebig HH, Smink KT, VanPuttem LM, Schuchhardt C. Comparison between macroscopic and microscopic evaluation of tumor responsiveness using subrenal capsule assay. Eur J Cancer Clin Oncol 1983; 19: 995–1009.
Levi FA, Blum JP, Lemaigre G, Bourut C, Reinberg A, Mathe G. A four-day subrenal capsule assay for testing the effectiveness of anticancer drugs against human tumors. Cancer Res 1984; 44: 2660–2667.
Fingert HJ, Treiman A, Pardee AB. Transplantation of human or rodent tumors into cyclosporinetreated mice; A feasible model for studies of tumor biology and chemotherapy. Proc Natl Acad Sci 1984; 81: 7927–7931.
Benett JA, Pilon VA, MacDowell R. Evaluation of growth and histology of human tumor xenografts implanted under the renal capsule of immunocompetent and immunodeficient mice. Cancer Res 1985; 45: 4963–4969.
Houchens DP, Ovejera AA, Barker AD. The therapy of human tumors in athymic mice. In: Houchens DP, Ovejera AA, eds. Proceeding of the symposium on the use of athymic mice in cancer research. Columbus: Gustav Fischer 1978; 267–280.
Oiseka R, Kloke O, Seeber S, Schmidt CG. Chemosensitization by cyclosporine A. Proc Am Asso Cancer Res 1986; 27: 400.
Kline I, Gang M, Tyrer DD, Mantel N, Venditti JM, Goldin A. Duration of drug levels in mice as indicated by residual antileukemic efficacy. Chemotherapy 1968; 13: 28–41.
Kelsen D. Chemotherapy of esophageal cancer. Semin Oncol 1989; 11: 159–168.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Terashima, M., Ikeda, K., Kawamura, S. et al. The usefulness of cyclophosphamide pretreatment for subrenal capsule assay against human esophageal cancer. The Japanese Journal of Surgery 21, 184–192 (1991). https://doi.org/10.1007/BF02470907
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02470907